Brown E - Search Results

1

SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications.

Brown E, Heerspink HJL, Cuthbertson DJ, Wilding JPH. Brown E, et al. Lancet. 2021 Jul 17;398(10296):262-276. doi: 10.1016/S0140-6736(21)00536-5. Epub 2021 Jun 30. Lancet. 2021. PMID: 34216571 Review.

2

Adrenocortical carcinoma: an unusual genetic cause!

Brown E, Hardy R, Weber A, Daousi C, Wieshmann H, Sheard J, Cuthbertson DJ. Brown E, et al. Clin Endocrinol (Oxf). 2012 Nov;77(5):787-8. doi: 10.1111/j.1365-2265.2012.04377.x. Clin Endocrinol (Oxf). 2012. PMID: 22414215 No abstract available.

3

Multidisciplinary management of refractory insulinomas.

Brown E, Watkin D, Evans J, Yip V, Cuthbertson DJ. Brown E, et al. Clin Endocrinol (Oxf). 2018 May;88(5):615-624. doi: 10.1111/cen.13528. Epub 2018 Mar 2. Clin Endocrinol (Oxf). 2018. PMID: 29205458 Review.

4

Newer GLP-1 receptor agonists and obesity-diabetes.

Brown E, Cuthbertson DJ, Wilding JP. Brown E, et al. Peptides. 2018 Feb;100:61-67. doi: 10.1016/j.peptides.2017.12.009. Peptides. 2018. PMID: 29412833 Review.

5

Longitudinal analysis of risk of non-alcoholic fatty liver disease in adulthood.

Cuthbertson DJ, Brown E, Koskinen J, Magnussen CG, Hutri-Kähönen N, Sabin M, Tossavainen P, Jokinen E, Laitinen T, Viikari J, Raitakari OT, Juonala M. Cuthbertson DJ, et al. Among authors: brown e. Liver Int. 2019 Jun;39(6):1147-1154. doi: 10.1111/liv.13993. Epub 2019 Apr 11. Liver Int. 2019. PMID: 30347485 Free article.

6

Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities.

Brown E, Wilding JPH, Barber TM, Alam U, Cuthbertson DJ. Brown E, et al. Obes Rev. 2019 Jun;20(6):816-828. doi: 10.1111/obr.12841. Epub 2019 Apr 10. Obes Rev. 2019. PMID: 30972878 Review.

7

A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter-2 inhibitors.

Brown E, Rajeev SP, Cuthbertson DJ, Wilding JPH. Brown E, et al. Diabetes Obes Metab. 2019 Apr;21 Suppl 2:9-18. doi: 10.1111/dom.13650. Diabetes Obes Metab. 2019. PMID: 31081592 Review.

8

Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes.

Hydes TJ, Summers N, Brown E, Alam U, Thomaides-Brears H, Wilding JPH, Cuthbertson DJ. Hydes TJ, et al. Among authors: brown e. Diabet Med. 2020 Nov;37(11):1793-1806. doi: 10.1111/dme.14356. Epub 2020 Jul 13. Diabet Med. 2020. PMID: 32619031 Review.

9

The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection.

Brown E, Wilding JPH, Alam U, Barber TM, Karalliedde J, Cuthbertson DJ. Brown E, et al. Ann Med. 2021 Dec;53(1):2072-2089. doi: 10.1080/07853890.2020.1841281. Ann Med. 2021. PMID: 33107349 Free PMC article. Review.

10

The prevalence of cardiac autonomic neuropathy in prediabetes: a systematic review.

Eleftheriadou A, Williams S, Nevitt S, Brown E, Roylance R, Wilding JPH, Cuthbertson DJ, Alam U. Eleftheriadou A, et al. Among authors: brown e. Diabetologia. 2021 Feb;64(2):288-303. doi: 10.1007/s00125-020-05316-z. Epub 2020 Nov 9. Diabetologia. 2021. PMID: 33164108 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

7,138 results

Search Page